Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Infinity Pharmaceuticals, Inc is a biotechnology business based in the US. Infinity Pharmaceuticals shares (INFI) are listed on the NASDAQ and all prices are listed in US Dollars. Infinity Pharmaceuticals employs 25 staff and has a trailing 12-month revenue of around USD$1.4 million.
|52-week range||USD$0.6 - USD$1.68|
|50-day moving average||USD$1.1109|
|200-day moving average||USD$1.0079|
|Wall St. target price||USD$2.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.336|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$1.4 million|
|Gross profit TTM||USD$-31,375,000|
|Return on assets TTM||-44.36%|
|Return on equity TTM||-474.68%|
|Market capitalisation||USD$71.2 million|
TTM: trailing 12 months
There are currently 166,370 Infinity Pharmaceuticals shares held short by investors – that's known as Infinity Pharmaceuticals's "short interest". This figure is 112.6% up from 78,256 last month.
There are a few different ways that this level of interest in shorting Infinity Pharmaceuticals shares can be evaluated.
Infinity Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Infinity Pharmaceuticals shares currently shorted divided by the average quantity of Infinity Pharmaceuticals shares traded daily (recently around 415925). Infinity Pharmaceuticals's SIR currently stands at 0.4. In other words for every 100,000 Infinity Pharmaceuticals shares traded daily on the market, roughly 400 shares are currently held short.
However Infinity Pharmaceuticals's short interest can also be evaluated against the total number of Infinity Pharmaceuticals shares, or, against the total number of tradable Infinity Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Infinity Pharmaceuticals's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Infinity Pharmaceuticals shares in existence, roughly 0 shares are currently held short) or 0.0042% of the tradable shares (for every 100,000 tradable Infinity Pharmaceuticals shares, roughly 4 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Infinity Pharmaceuticals.
Find out more about how you can short Infinity Pharmaceuticals stock.
We're not expecting Infinity Pharmaceuticals to pay a dividend over the next 12 months.
Infinity Pharmaceuticals's shares were split on a 1:4 basis on 13 September 2006. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Infinity Pharmaceuticals shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Infinity Pharmaceuticals shares which in turn could have impacted Infinity Pharmaceuticals's share price.
Over the last 12 months, Infinity Pharmaceuticals's shares have ranged in value from as little as $0.6 up to $1.68. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Infinity Pharmaceuticals's is 1.8759. This would suggest that Infinity Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. It offers IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the enzyme phosphoinositide-3-kinase-gamma Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib, as well as duvelisib program for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol-Myers Squibb Company. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
Everything we know about the NewRez IPO, plus information on how to buy in.
Everything we know about the Perella Weinberg IPO, plus information on how to buy in.
Everything we know about the Nanobiotix IPO, plus information on how to buy in.
Everything we know about the Diversey IPO, plus information on how to buy in.
Everything we know about the Certara IPO, plus information on how to buy in.
Everything we know about the Arrival IPO, plus information on how to buy in.
Everything we know about the iSpecimen IPO, plus information on how to buy in.
Everything we know about the IDEX Biometrics ASA IPO, plus information on how to buy in.
Steps to owning and managing MYSZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing MG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.